Fosun Pharma USA Inc. established in 2017, is a subsidiary of a leading global healthcare group, Fosun Pharma (SSE: 600196) (SEHK:2196) and Fosun International Limited (SEHK: 656), a leading conglomerate and investment company.
Our management team has many years of experience in the pharma industry and bring a strong commitment to the growth of Fosun Pharma USA Inc.
Jeremy is responsible for Commercial Operations, BD and Investment activities in the US.
Jeremy brings 25+ years of industry experience in Commercial Operation and Strategy in both brand and generic pharmaceuticals to Fosun Pharma USA. He has previously held positions of ever increasing responsibility at Merck, Cubist, EKR Therapeutics, AuroMedics, American Regent and Slayback Pharma where he was Vice President of Sales before joining Fosun Pharma USA.
Dr. Lijun Wu is the Chief Scientific Officer of Fosun Pharma USA, Inc. and Fosun Pharmaceutical Development Company. Prior to joining Fosun Pharma in 2018, she was an Entrepreneur-in-Residence at Atlas Venture and Senior Vice President of Preclinical and Early positions in the biotech and pharmaceutical industry including Vice President of Biology and Preclinical R&D at Concert Pharmaceuticals, Vice President of Discovery Research at Resolvyx Pharmaceuticals, Executive Director of Cardiovascular Research at the Novartis Institutes for BioMedical Research, and Director of Molecular and Cellular Pharmacology at Millennium Pharmaceuticals.
Dr. Wu is a seasoned executive with >20-years of experience in startup, established biotech, and large pharmaceutical companies. She is an author of over 60 peer-reviewed publications an inventor on a number of patents, and the recipient of Massachusetts High Tech’s “Women to Watch” award. She has been serving on the advisory council of IBBS/Johns Hopkins School of Medicine and is a member of JHU’s Society of Scholars.
Dr. Wu received her Ph.D. in Biochemistry, Molecular Biology and Cell Biology from Northwestern University and completed a postdoctoral fellowship at Johns Hopkins University School of Medicine.
Qun has 10 years of experience in Regulatory Affairs, including five years of CMC experience in oral solid dosage form and five years CMC experience in injectable/injection products, with increased responsibilities at Prinston Pharmaceutical and Jiangsu Hengrui Medicine for US filings.
Qun had been an organic chemist for 10 years in the R&D of FMC Corporation and analytical chemist for 5 years in the R&D analytical laboratory of Huahai US Inc. prior to transferring into regulatory affairs.
Huong Nguyen is currently Vice President, General Counsel, of Fosun Pharma USA Inc. She has spent the majority of her nearly two-decade law practice actively working in the pharmaceutical industry as both an in-house counsel and a private practitioner. Throughout this time she has partnered with a wide variety of cross-functional groups, and has directly counseled senior management and Boards of Directors in her areas of expertise.
Huong spent the early years of her legal career in private practice at two consecutive national (US) law firms as a commercial and IP litigator and IP counsel. Thereafter, she spent almost ten years at a specialty pharmaceutical company as in-house counsel, with increasing responsibilities through the years in litigation, IP, and employment matters. While in-house, Huong also spearheaded internal and government investigations that resulted in her appearing before the US Federal Trade Commission, US Department of Justice, and State Attorneys General in defense of the company. She left her first pharmaceutical company for private practice in order to expand her experience in M&A and BD and commercial transactions.
In 2019, Huong joined Fosun as General Counsel, with deep and wide-ranging experiences in litigation, IP, compliance, M&A, BD and commercial transactions, and employment. During the COVID-19 pandemic, Huong also assisted Fosun in the sales and distribution of medical supplies and devices, including PPE and Fosun’s own RT-PCR and Antibody Detection Kits.
Huong received her BA at the University of California, Los Angeles and her JD at the University of California, Hastings College of the Law.
Chris is responsible for BD&L activities in the US and has 25 years of pharmaceutical industry experience spanning business and scientific disciplines.
Chris’ prior scientific experience includes positions of increasing responsibility at Organogenesis, Genetics Institute/Wyeth, and Novartis (NIBR). His business and corporate development experience includes positions of increasing responsibility at Indevus Pharmaceuticals, Endo International, and Teva Pharmaceuticals and encompasses a wide range of transactions including: in- and out-licensing, asset acquisitions and divestitures, and M&A in both the generics and branded pharmaceutical spaces.
Chris received his B.S. in Biology from the University of Massachusetts at Lowell, his A.L.M with a concentration in molecular biology and original thesis work in RNA interference from Harvard University, and his M.B.A. from Boston University.